1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors TSID 12064

Awaiting development [GID-TA11594] Expected publication date: TBC

  • Project information
  • Project documents

37233-Atezolizumab-Tiragolumab-for-Solid-Tumours-V1.0-MAY2024-NON-CONF.pdf (nihr.ac.uk)